SUT
BBIO icon

SC US (TTGP)’s BridgeBio Pharma BBIO Stock Holding History

SC US (TTGP)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139M Hold
1,860,364
– – 0.43% 8
2026
Q1 		$138M Hold
1,860,364
– – 1.49% 7
2025
Q4 		$142M Hold
1,860,364
– – 1.02% 7
2025
Q3 		$96.6M Hold
1,860,364
– – 0.6% 9
2025
Q2 		$80.3M Hold
1,860,364
– – 0.57% 9
2025
Q1 		$64.3M Hold
1,860,364
– – 0.61% 8
2024
Q4 		$51M Hold
1,860,364
– – 0.41% 12
2024
Q3 		$47.4M Hold
1,860,364
– – 0.35% 14
2024
Q2 		$47.1M Hold
1,860,364
– – 0.38% 13
2024
Q1 		$57.5M Hold
1,860,364
– – 0.43% 13
2023
Q4 		$75.1M Hold
1,860,364
– – 0.62% 11
2023
Q3 		$49.1M Hold
1,860,364
– – 0.45% 13
2023
Q2 		$32M Hold
1,860,364
– – 0.3% 13
2023
Q1 		$30.8M Hold
1,860,364
– – 0.36% 15
2022
Q4 		$14.2M Hold
1,860,364
– – 0.19% 15
2022
Q3 		$18.5M Hold
1,860,364
– – 0.21% 15
2022
Q2 		$16.9M Hold
1,860,364
– – 0.2% 14
2022
Q1 		$18.9M Hold
1,860,364
– – 0.12% 16
2021
Q4 		$31M Hold
1,860,364
– – 0.15% 13
2021
Q3 		$87.2M Hold
1,860,364
– – 0.49% 9
2021
Q2 		$113M Sell
1,860,364
-684,374
-27% -$39.1M 0.72% 9
2021
Q1 		$157M Hold
2,544,738
– – 0.94% 7
2020
Q4 		$181M Hold
2,544,738
– – 1.08% 7
2020
Q3 		$95.5M Hold
2,544,738
– – 0.92% 7
2020
Q2 		$83M Hold
2,544,738
– – 4.87% 3
2020
Q1 		$73.8M Hold
2,544,738
– – 5.65% 4
2019
Q4 		$89.2M Hold
2,544,738
– – 3.83% 6
2019
Q3 		$54.6M Hold
2,544,738
– – 2.42% 8
2019
Q2 		$68.6M Buy
+2,544,738
New +$69.4M 4.69% 7

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

SC US (TTGP)'s BBIO Position: Q2 2026 in Review

SC US (TTGP) held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 1,860,364 shares worth $139M. The position accounts for 0.43% of the portfolio, ranked #8.

SC US (TTGP) first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $181M in Q4 2020. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • SC US (TTGP) held 1,860,364 shares of BridgeBio Pharma worth $139M as of Q2 2026.
  • SC US (TTGP) left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.43% of SC US (TTGP)'s portfolio in Q2 2026, its #8 holding.
  • SC US (TTGP) first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • SC US (TTGP)'s BridgeBio Pharma position peaked at $181M in Q4 2020.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on SC US (TTGP)'s 13F filing for Q2 2026, filed 14 Aug 2026.